Edelman’s Frankfurt office sees its contract with LEO Pharma renewed following a successful year.
The renewed contract will involve Edelman having responsibility for the strategic planning and implementation of trade activities in the field of blood coagulation disorders in Germany, said LEO Pharma.
“Last year Edelman successfully supported us with their health industry expertise, which was essential in the communications process during our first benefit assessment in the area of dermatology,” said LEO Pharma spokesman Thomas Schick.
“We are happy to work with them now in the thrombosis business division”.
With this renewed contract, Edelman is continuing to expand its portfolio of clients in the field of classical technical communication, the agency said.
“With LEO, we’re now working on a couple of topics – not campaigns,” Martin Flörkemeier, managing director of Edelman in Germany, told PMLiVE.
“Knowing that they’ve just awarded us this new piece of work because of their high satisfaction with our strategic competence, service quality and exactly the right team match, we would hope that this partnership will remain healthy and potentially grow further in the future.”
Founded in 1908, LEO Pharma provides medical solutions in more than 100 countries. It is headquartered in Denmark, owned by the LEO Foundation and employs 4,800 staff worldwide.